Healthcare Industry News: Wound Dressing
News Release - April 24, 2008
ImmuneRegen(R) and BioCure Collaborate on Novel Wound-Healing ProductApplication to Combine Wound-Healing Activity with an Easily Applied Liquid Bandage
SCOTTSDALE, Ariz.--(HSMN NewsFeed)--ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO ), today announced an agreement with BioCure, Inc., to design and develop a novel wound-healing product. Under the recently executed Material Transfer Agreement (MTA), BioCure will utilize ImmuneRegen’s Homspera™ for the development of a combination product composed of the potential wound-healing therapeutic Homspera and BioCure’s GelSpray™, a spray-on liquid bandage that has obtained 510(k) market clearance from the FDA.
“Homspera can directly enhance fibroblast growth,” said Hal Siegel, Ph.D., ImmuneRegen’s vice president and chief scientific officer. “In addition, we have shown Homspera can stimulate blood-forming stem cells to produce white blood cell precursors, particularly, granulocytes and macrophages, which play a role in wound repair. This combination of enhanced fibroblast growth and increased immune system cells suggest a role for Homspera in improving wound and lesion healing.”
The combination of Homspera with BioCure’s Wound Dressing may provide a sterile wound healing product in an easily applied spray-on configuration. BioCure’s hydrogel technology allows the liquid bandage to be applied painlessly to hard-to-cover areas such as between fingers and toes or over joints. The product conforms well to the wound and surrounding tissues, maintaining a moist environment that has been proven to accelerate healing.
"We welcome the opportunity to collaborate with ImmuneRegen on innovative products with the aim of benefiting patients and healthcare practitioners. We believe that the combination of the technologies and experienced R&D teams of both companies could lead to breakthrough treatments in wound healing," said Andrew Maslaveckas, BioCure’s co-founder and chief operating officer.
According to Michael Wilhelm, ImmuneRegen president and CEO, “This could drive significant partnering opportunities, as we believe wound-healing products remain in high demand. The potential combination could make an excellent product for our soldiers in the battlefield in addition to benefiting the public at large.”
About BioCure, Inc.
BioCure, Inc. is a medical device company that develops proprietary hydrogel technology for use throughout the human body. BioCure’s technology platform and IP position allow it to develop novel applications for hydrogel technology. This technology will also be leveraged for future innovations capable of incorporating active ingredients and biologics for enhanced clinical outcomes where standard devices fail. Development of medical devices based upon hydrogel technology allows physicians to treat a range of diseases. Additionally, the technology allows for injection-based procedures, thereby minimally invasive procedures, while the polymer cures in situ. The goals of this technology platform include reduced hospitalizations, improved quality of life, tailored therapy for patient-specific disease and a cost-efficient alternative to current treatment modalities. For more information, please visit www.biocure.com.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO ), is a development-stage biotechnology company focused on the research, development and licensing of Homspera™, an adult stem cell active compound that can potentially regenerate and strengthen the immune system. To advance its mission, the Scottsdale, Arizona-based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including statements about the potential for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-KSB for the twelve months ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
Source: ImmuneRegen BioSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.